Australian sleep health giant Resmed has locked down an exemption from Donald Trump’s sweeping trade tariffs. Resmed produces ...

Shares of ResMed Inc. jumped 10.10% to $236.10 Thursday, on what proved to be an all-around favorable trading session for the ...

Matthew Haupt from Wilson Asset Management and Tim Johnston from Tyndall Asset Management discuss rate cut winners and losers ...

Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...

EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...

Resmed has named Salli Schwartz as chief investor relations officer, where she will lead the company’s global investor relations function and report to Mick Farrell, chairman of the board ...

Resmed reported third quarter 2025 revenues of $1.3 billion, an increase of 8% over the same quarter the prior year.

UBS lowered the firm’s price target on ResMed (RMD) to $285 from $290 and keeps a Buy rating on the shares.Stay Ahead of the Market: Discover ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight ...

Australian sleep device giant ResMed has secured an exemption from Donald Trump’s global tariffs in a major win for the ...